NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Actuate Therapeutics Inc.
Tesaro, Inc.
AbbVie
AbbVie
Tesaro, Inc.
AbbVie
Memorial Sloan Kettering Cancer Center
DEKA Biosciences
MedImmune LLC